SELLAS Life Sciences Group Quarterly Income Statement
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.65+0.39 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group revenue and earnings
SELLAS Life Sciences Group reported a net loss of $9.6 million, compared with a loss of $6.6 million a year earlier. Diluted earnings per share came in at -$0.05.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Operating Expenses | — | — | — | — | — | — | — | — | — | — | 8.18M | 9.36M |
| Research & Development | 6.27M | 5.13M | 4.73M | 4.22M | 3.87M | 3.21M | 4.44M | 4.36M | 5.19M | 5.11M | 5.10M | 5.81M |
| Selling, General & Admin | — | — | 3.52M | 2.87M | 3.00M | 2.86M | 2.48M | 2.97M | 2.44M | 4.53M | 3.08M | 3.55M |
| Operating Income | -10.63M | -9.25M | -8.26M | -7.08M | -6.87M | -6.06M | -6.92M | -7.33M | -7.62M | -9.64M | -8.18M | -9.36M |
| Other Income (Expense) | 1.02M | 845.00K | 597.00K | 292.00K | 272.00K | 250.00K | 181.00K | 221.00K | 151.00K | 79.00K | 41.00K | 94.00K |
| Net Income | -9.61M | -8.41M | -7.66M | -6.79M | -6.60M | -5.81M | -6.74M | -7.11M | -7.47M | -9.57M | -8.14M | -9.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.05 | -0.05 | -0.05 | -0.06 | -0.07 | -0.07 | -0.06 | -0.10 | -0.13 | -0.21 | -0.23 | -0.33 |
| EPS (Diluted) | -0.05 | -0.05 | -0.05 | -0.06 | -0.07 | -0.07 | -0.06 | -0.10 | -0.13 | -0.21 | -0.23 | -0.33 |
| Shares Outstanding (Basic) | 189.18M | 172.48M | — | 108.40M | 98.56M | 87.76M | — | 68.25M | 57.63M | 44.81M | — | 28.36M |
| Shares Outstanding (Diluted) | 189.18M | 172.48M | — | 108.40M | 98.56M | 87.76M | — | 68.25M | 57.63M | 44.81M | — | 28.36M |
This table shows 12 quarterly periods of SELLAS Life Sciences Group's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SLS's reporting calendar. What is a income statement?